We actually need to know a lot of information about the low LDL/apabetalone group in addition to HDL. Were they younger than the low LDL/placebo group? Did they have lower blood pressure? Were fewer of them cigarette smokers? Were they less obese? Without this and other info, it’s not certain that the lower CVD was due to the treatment. No doubt the statisticians are looking at this question.